Session 4 Chair: Thomas Hartung

Thomas Hartung, MD, PhD
INSTITUTION / COMPANY : 

The Johns Hopkins University
Bloomberg School of Public Health

CURRENT APPOINTMENTS:
Director, CAAT
Professor, Evidence Based Toxicology
Join Appointment: Department of Molecular Microbiology and Immunology

RESEARCH AND PROFESSIONAL EXPERIENCE:
The main goal of my work is toward a paradigm shift in toxicity testing to improve public health. Due to my background as head of the European Center for the Validation of Alternative Methods of the European Commission (2002-2008), I am involved in the implementation of the 2007 NRC vision document “Toxicity Testing in the 21st Century – a vision and a strategy”. I have furthered the translation of concepts of evidence-based medicine to toxicology (evidence-based toxicology). This aims for systematic assessment of the quality of all tools for regulatory toxicology and the development of new approaches based on annotated pathways of toxicity (the Human Toxome).

I have a broad background in clinical and experimental pharmacology and toxicology documented in more than 350 publications. Previous work centered on the immune recognition of bacteria, including pyrogen testing, and the induced inflammatory response. In experimental and clinical approaches, the pharmacological modulation of these responses was studied. I have relocated to the US early 2009 and established beside the directorship for the Center for Alternatives to Animal Testing (CAAT) a laboratory for developmental neurotoxicity research based on genomics and metabolomics the respective technologies were made available by a Thought-Leader Award from Agilent.